• Publications
  • Influence
Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.
179 Background: We found in our lab that capecitabine (CAP), the prodrug of 5-FU, and temozolomide (TEM) were synergistic in inducing apoptosis in BON neuroendocrine tumor (NET) cell lines. We wereExpand
  • 58
  • 6
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience
PurposeWe evaluated the efficacy and safety of capecitabine and temozolomide (CAPTEM) in patients with metastatic neuroendocrine tumors (NETs) to the liver. This regimen was based on our studies withExpand
  • 170
  • 2
Treatment of Multiple Endocrine Neoplasia 1/2 Tumors: Case Report and Review of the Literature
Background: Neuroendocrine tumors are uncommon tumors that are histopathologically and biologically heterogeneous and include the multiple endocrine neoplasia (MEN) 1 and 2 syndromes. The morbidityExpand
  • 11
Prospective phase II trial of GTX in metastatic pancreatic cancer: Laboratory and clinical studies.
209 Background: We found that in pancreatic cancer (PC) cells, when gemcitabine, docetaxel, capecitabine (GTX) are given in a sequence and time specific manner, it 1) increased Bax, Bak, Fas andExpand
  • 5
Prospective phase II study of inoperable pancreatic adenocarcinoma with neoadjuvant gemcitabine, docetaxel, and capecitabine (GTX).
274 Background: Chemoradiation (CRT) is used in unresectable pancreatic cancer (PC) to convert patients to a resectable state. Those who go to surgery can have a similar survival as those initiallyExpand
  • 3
The efficacy and safety of the capecitabine/temozolomide (CAPTEM) regimen in the treatment of well-differentiated neuroendocrine tumors with liver metastasis after failure of previous therapy:
308 Background: We have observed efficacy and tolerability of the CAPTEM regimen in pNET. We conducted a retrospective review of patients with liver metastasis from any NET, including carcinoid, whoExpand
  • 1
Phase I trial of sorafenib in hepatocellular carcinoma (HCC) patients after liver transplantation (LT).
TPS172 Background: Liver transplantation offers long term survival for 75-80% of HCC patients within Milan and UCSF criteria. For those who fall outside, rates of recurrence are higher. There are noExpand
Capecitabine (Xeloda®) and Temozolomide (Temodar®) as a Potential Therapy for Pituitary Tumors
We reviewed various cases and clinical studies of aggressive pituitary adenomas utilizing Capecitabine (Xeloda®) and temozolomide (Temodar®), hereon referred to as CAPTEM, as their last line ofExpand